Comprehensive Mutational Analysis of the BRCA1-Associated DNA Helicase and Tumor-Suppressor FANCJ/BACH1/BRIP1
Open Access
- 22 February 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 19 (6), 1015-1025
- https://doi.org/10.1158/1541-7786.mcr-20-0828
Abstract
FANCJ (BRIP1/BACH1) is a hereditary breast and ovarian cancer (HBOC) gene encoding a DNA helicase. Similar to HBOC genes, BRCA1 and BRCA2, FANCJ is critical for processing DNA inter-strand crosslinks (ICL) induced by chemotherapeutics, such as cisplatin. Consequently, cells deficient in FANCJ or its catalytic activity are sensitive to ICL-inducing agents. Unfortunately, the majority of FANCJ clinical mutations remain uncharacterized, limiting therapeutic opportunities to effectively use cisplatin to treat tumors with mutated FANCJ. Here, we sought to perform a comprehensive screen to identify FANCJ loss-of-function (LOF) mutations. We developed a FANCJ lentivirus mutation library representing approximately 450 patient–derived FANCJ nonsense and missense mutations to introduce FANCJ mutants into FANCJ knockout (K/O) HeLa cells. We performed a high-throughput screen to identify FANCJ LOF mutants that, as compared with wild-type FANCJ, fail to robustly restore resistance to ICL-inducing agents, cisplatin or mitomycin C (MMC). On the basis of the failure to confer resistance to either cisplatin or MMC, we identified 26 missense and 25 nonsense LOF mutations. Nonsense mutations elucidated a relationship between location of truncation and ICL sensitivity, as the majority of nonsense mutations before amino acid 860 confer ICL sensitivity. Further validation of a subset of LOF mutations confirmed the ability of the screen to identify FANCJ mutations unable to confer ICL resistance. Finally, mapping the location of LOF mutations to a new homology model provides additional functional information.Implications:. We identify 51 FANCJ LOF mutations, providing important classification of FANCJ mutations that will afford additional therapeutic strategies for affected patients.Other Versions
Funding Information
- NIH (R01 CA225018)
- NIH (R01 CA225018)
This publication has 66 references indexed in Scilit:
- Non-Bloom syndrome-associated partial and total loss-of-function variants of BLM helicaseProceedings of the National Academy of Sciences of the United States of America, 2012
- Fanconi anemia and Bloom's syndrome crosstalk through FANCJ–BLM helicase interactionTrends in Genetics, 2012
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencingProceedings of the National Academy of Sciences of the United States of America, 2011
- Targeting the FANCJ–BRCA1 interaction promotes a switch from recombination to polη-dependent bypassOncogene, 2010
- FANCJ Helicase Uniquely Senses Oxidative Base Damage in Either Strand of Duplex DNA and Is Stimulated by Replication Protein A to Unwind the Damaged DNA Substrate in a Strand-specific MannerOnline Journal of Public Health Informatics, 2009
- Protein structure prediction on the Web: a case study using the Phyre serverNature Protocols, 2009
- Welcome the Family of FANCJ-like Helicases to the Block of Genome Stability Maintenance ProteinsCellular and Molecular Life Sciences, 2008
- The arginine finger of the Bloom syndrome protein: its structural organization and its role in energy couplingNucleic Acids Research, 2007
- The FANCJ/MutLα interaction is required for correction of the cross-link response in FA-J cellsThe EMBO Journal, 2007
- Inhibition of BACH1 (FANCJ) helicase by backbone discontinuity is overcome by increased motor ATPase or length of loading strandNucleic Acids Research, 2006